Osimertinib resistance-based immune prognostic related gene signature in EGFR mutant lung adenocarcinoma, in which PSMD11 promotes tumor progression.

ABSTRACT:

Background

At present, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment, as the first-line treatment of lung adenocarcinoma (LUAD) with EGFR mutation, has achieved good clinical efficacy, but most patients will eventually develop acquired resistance. The objective of this study is to accurately identify drug-resistant LUAD patients who can benefit from other treatments by constructing a predictive model for EGFR-TKIs resistance.

Methods

Based on the differentially expressed genes (DEGs) between osimertinib (OSI)-resistant cells (PC9OR, H1975OR) and OSI-sensitive LUAD cells (PC9, H1975), the EGFR mutant LUAD prognosis-related genes from The Cancer Genome Atlas (TCGA), and the immune genes from ImmPort and InnateDB websites, we constructed an i

SUBMITTER: Bai Y 

PROVIDER: S-EPMC12541842 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature